Loading Page..

Knowledge Content Library

125
Using Preference Probabilities as a Surrogate for Market Forecasts
Presented by D. Johnson (Eli Lilly) at 2002 DAAG Conference in Las Vegas. Innovative way to use preference probabilities to make market forecasts where doing so directly would be a daunting task.

127
Expected Internal Rate of Return as a Prioritization Metric
Presented by J. Mauer (BristolMyersSquibb) at 2002 DAAG Conference in Las Vegas. Discussion of the use of expected IRR as an addition to other financial metrics (e.g., eNPV).

131
DA at Bristol-Myers Squibb
Presented by Kazuo Ezawa (BristolMyersSquibb) at 2002 DAAG Conference in Las Vegas. Discussion of the evolution of DA at the company and the challenges and keys to success in implementation.

94
Are you ready for the MODA of all portfolio prioritization approaches or is SODA still appropriate?
Presented by Jeff Stonebreaker (Bayer) at 2001 DAAG Conference in Houston. Multi-objective analysis applied to portfolio problems in Bayer.

98
Five Essential Keys to Successful Portfolio Management
Presented by Stuart Harris (GlaxoSmithKline) at 2001 DAAG Conference in Houston. Overview of portfolio management and five keys - corporate buy-in, risk management, revenue stream, efficiency of investment, and profit.

99
Generating Actionable Strategic Alternatives
Presented by Rick Bayney (BristolMyersSquibb) at 2001 DAAG Conference in Houston. Discussion of developing strategies as a key part of portfolio analysis.

101
Implementation of Decision Analysis at Novartis
Presented by (Novartis) at 2001 DAAG Conference in Houston. Discussion of the the issues at Novartis during implementation and adoption of Decision Analysis.

80
Decision Analysis to Evaluate Possible Early Allocation of Phase 3 Resources
Presented by C. Hallford (Eli Lilly) at 2000 DAAG Conference in Calgary. An analysis of the benefits and risks of accelerating the timing of allocating Phase 3 resources.

84
Proof of Concept in Drug Development
Presented by Stuart Harris (GlaxoSmithKline) at 2000 DAAG Conference in Calgary. Application of value of imperfect information analysis to proof of concept in drug development.

85
Lessons about Options from a Pharmaceutical R&D Project
Presented by Tom Spradlin (Eli Lilly) at 2000 DAAG Conference in Calgary. Discussion of options applications to the phased decisions inherent in the drug development cycle.

87
Instructional Requirements for Practitioners of Decision Analysis: A Descriptive Study
Presented by Richard Justice (Eli Lilly) at 2000 DAAG Conference in Calgary. Descriptive study of skills needed by practitioners of decision analysis, based on a survey of literature and a pilot-study of practitioners of DA using an internet-based survey.

66
Thinking of Values at Lilly
Presented by Tom Spradlin (Eli Lilly) at 1998 DAAG Conference in San Francisco. Overview of strategy development at Lilly and the use of value focused thinking to inform that strategy.

532
Estimating Predictive Probability of Success
Shaun Comfort, Publications (Journal Article)

Stay connected